OakChart

PMGC Holdings Inc

ELABHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:54 PM ET

1.58-0.11 (-6.51%)
2026-11-11 22:15 CET
Market cap
1.37 USD m
Revenue, TTM
2.58 USD m
Net income, TTM
-13.49 USD m
Free cash flow, TTM
-8.99 USD m
EPS diluted, TTM
-1,815.13
P/E
-
Compare

Price

ELAB against its 20, 50 and 200-day averages
2050200
0.00200.00400.00600.00800.006.4M12.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ELABclose 1.5820-day 2.3350-day 3.40200-day 27.371.58

99.9% under the 52-week high of 1,471.20 on 11 Nov 2025. 52-week low 1.41 on 10 Nov 2026. Last 15 sessions, 102.8% high to low

Volume 0.30× normal · the line is the 50-bar volume average

Profile

ELAB
52-week range, 0% of the way up
1.411,471

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

Employees34
IPONov 21, 2023
Beta-0.23
ATR, 14d0.30
Rel volume0.30
Short float2.30%
Insider own0.00%
Inst own2.98%

Snapshot

6 groups

Valuation

Index-
Market Cap1.28M
Enterprise Value-3.27M
Income-13.49M
Sales2.58M
Book/sh27.20
Cash/sh23.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees34
IPONov 21, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S0.50
P/B0.06
P/C0.07
P/FCF-
EV/EBITDA-
EV/Sales-1.27
Quick Ratio1.30
Current Ratio1.36
Debt/Eq0.85
LT Debt/Eq0.27
Option/ShortNo / Yes

Earnings

EPS (ttm)-1815.13
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y74.26% 15.55%
Sales past 3/5Y-8.34% -
EPS Y/Y TTM99.47%
Sales Y/Y TTM-
EPS Q/Q98.41%
Sales Q/Q-
Earnings-
EPS/Sales Surpr.- -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own2.98%
Inst Trans0.02%
ROA-59.06%
ROE-105.22%
ROIC-63.60%
Gross Margin10.31%
Oper. Margin-477.02%
Profit Margin-522.97%
SMA20-32.28%
SMA50-53.59%
SMA200-94.23%
Trades-

Technical

Shs Outstand0.81M
Shs Float0.81M
Short Float2.30%
Short Ratio0.07
Short Interest0.02M
52W High1471.20 -99.89%
52W Low1.41 12.06%
Volatility17.72% 11.37%
ATR (14)0.30
RSI (14)18.39
Beta-0.23
Rel Volume0.30
Avg Volume254.72K
Volume75,840

Performance

Perf Week-17.71%
Perf Month-46.62%
Perf Quarter-82.38%
Perf Half Y-92.02%
Perf YTD-99.56%
Perf Year-99.89%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom-
Target Price-
Prev Close1.69
Price1.58
Change %-6.51%

Peers

Mkt cap
TickerCompanyMkt cap
MTVAMetaVia Inc9.49M
AZTRAzitra Inc3.59M
SKYESkye Bioscience Inc4.06M
SRRKScholar Rock Holding Corp5.68B
OGENOragenics Inc1.57M
VKTXViking Therapeutics Inc3.63B
FBIOFortress Biotech Inc67.04M
IGCIGC Pharma Inc22.82M
CDTCDT Equity Inc0.52M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • PMGC Holdings Inc. Announces Strategic Share Acquisition in Australian Space Technology Company Orbit2Orbit (GlobeNewswire) +6.96%
  • NorthStrive Biosciences Announces Results from EL-32 Preclinical Combination Study with Semaglutide and Plans for Next Phase of Development (GlobeNewswire) -14.06%
  • PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update (GlobeNewswire)
  • PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy (GlobeNewswire) -8.90%
  • NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs (GlobeNewswire) -23.22%
  • PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings (GlobeNewswire)
  • NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications (GlobeNewswire)
  • PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio (GlobeNewswire) +6.33%
  • PMGC Holdings Signs Orbit2Orbit Term Sheet for Microgravity Muscle Research (InvestorsHub) -12.73%
  • PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss (GlobeNewswire)
  • NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight (GlobeNewswire) +9.18%
  • PMGC Holdings Inc. Announces Anticipated Reverse Stock Split (GlobeNewswire) -32.49%
  • PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially (GlobeNewswire)
  • PMGC Holdings Confirms Compliance with Nasdaq's New $5 Million Market Value of Listed Securities Requirement (GlobeNewswire) -6.96%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-8820-53249.28-222181.68-470741.04-65924.62-3787.418-1815.1341
Period202020212022202320242025TTM
EPS, quarterly-94820.88-90775.44-79674-2419.2-379.814-1178.184-519.17-111.748-6.032
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00.0010.766000.592.58
Period202020212022202320242025TTM
Sales, quarterly0.6150.6060.527000.2860.3040.6821.307
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00000.0010.0080.615
Period202020212022202320242025MRQ
Shares, quarterly0000.0010.0020.0030.0080.1940.615
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue2.580.590.000.000.770.000.00
Cost of Goods Sold Incl. D&A2.310.520.080.000.320.000.00
Gross Profit0.270.07-0.08-0.000.44-0.000.00
Selling, General and Administrative Excl. Other12.076.953.571.142.030.760.13
Research and Development0.410.130.020.010.230.120.07
Other Operating Expense0.500.500.000.000.200.030.00
Operating Income-12.30-7.38-3.66-1.14-1.79-0.79-0.13
Interest Expense2.210.550.740.000.000.00-
Unusual Expense-0.50-0.03-0.370.520.010.000.00
Net Income Before Taxes-13.54-7.75-4.02-1.66-1.80-0.78-0.13
Income Taxes0.030.030.000.000.000.000.00
Consolidated Net Income-13.57-7.78-4.02-1.66-1.80-0.78-0.13
Net Income From Continuing Operations-13.57-7.78-4.02-1.66-1.80-0.78-0.13
Net Income-13.49-7.71-6.25-4.30-1.80-0.78-0.13
EPS (Recurring)-28.37-3,797.52-68,652.19-430,805.95-220,162.11-53,252.94-8,823.99
EPS (Basic, Before Extraordinaries)-1,815.13-3,787.42-65,924.62-470,741.04-222,181.68-53,249.28-8,820.00
EPS (Diluted)-1,815.13-3,787.42-65,924.62-470,741.04-222,181.68-53,249.28-8,820.00
EBITDA-11.74-7.27-3.57-1.14-1.78-0.78-0.13
Non-Operating Income (Expense)0.480.140.010.010.000.00-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense0.21-0.020.090.250.170.14-
Price To Sales Ratio2.291.23-11.47---
Gross Margin10.3112.68--57.72-244.01-
Operating Margin-477.02-1,250.11---233.37-94,928.90-
Net Margin-522.97-1,306.28---234.94-94,889.84-
Shares Outstanding0.620.010.000.000.000.000.00
Market Capitalization1.371.370.5731.6831.68--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q2
Total Revenue1.310.680.300.290.000.000.530.61
Cost of Goods Sold Incl. D&A1.200.610.260.242E-050.020.140.17
Gross Profit0.100.070.050.04-2E-05-0.020.390.44
Selling, General and Administrative Excl. Other3.923.392.512.241.011.191.271.79
Research and Development0.310.050.030.010.070.020.100.05
Other Operating Expense0.000.000.500.000.000.000.040.06
Operating Income-3.82-3.32-2.97-2.19-1.01-1.20-0.92-1.41
Interest Expense0.641.040.340.202E-060.010.650.03
Unusual Expense-1.350.64-0.020.23-0.300.06-0.07-0.03
Net Income Before Taxes-2.96-4.99-2.97-2.62-0.58-1.58-1.50-1.41
Income Taxes0.000.000.030.000.000.000.000.00
Consolidated Net Income-2.96-4.99-3.00-2.62-0.58-1.58-1.50-1.41
Net Income From Continuing Operations-2.96-4.99-3.00-2.62-0.58-1.58-1.50-1.41
Net Income-2.94-4.97-2.98-2.59-0.56-1.57-1.50-1.41
EPS (Recurring)-7.97-101.61-521.72-1,104.92-521.31-2,354.00-82,105.08-91,985.53
EPS (Basic, Before Extraordinaries)-6.03-111.75-519.17-1,178.18-379.81-2,419.20-79,674.00-90,775.44
EPS (Diluted)-6.03-111.75-519.17-1,178.18-379.81-2,419.20-79,674.00-90,775.44
EBITDA-3.51-3.16-2.91-2.16-1.01-1.19-0.92-1.38
Non-Operating Income (Expense)0.150.010.310.010.14-0.310.00-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.170.010.010.010.02-0.060.05-
Price To Sales Ratio2.292.093.46---0.754.29
Gross Margin7.9910.4215.6314.95--74.1772.09
Operating Margin-292.22-487.05-975.30-767.53---174.22-232.58
Net Margin-225.12-728.34-980.71-907.27---284.61-233.27
Shares Outstanding0.620.190.010.000.000.000.000.00
Market Capitalization1.3711.602.873.943.193.274.1010.05

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments5.973.983.331.150.410.01
Short Term Receivables0.340.010.000.010.000.00
Inventories0.100.000.000.240.190.00
Other Current Assets0.462.061.590.090.030.00
Total Current Assets6.876.054.921.500.640.02
Net Property, Plant & Equipment2.130.000.000.330.030.00
Total Investments and Advances0.000.140.000.010.000.00
Intangible Assets3.872.800.000.000.000.00
Other Assets0.000.000.270.050.000.00
Total Assets12.878.995.191.890.670.02
Short Term Debt Incl. Current Port. of LT Debt1.590.000.000.110.000.02
Accounts Payable0.700.000.000.220.100.00
Other Current Liabilities1.661.801.300.260.120.02
Total Current Liabilities3.941.801.300.590.220.04
Long Term Debt1.060.000.070.170.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.03-----
Other Liabilities0.000.530.000.000.000.00
Total Liabilities5.032.331.360.760.220.04
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.846.663.831.130.45-0.02
Total Shareholders Equity7.846.663.831.130.45-0.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity7.846.663.831.130.45-0.02
Total Liabilities & Stockholders Equity12.878.995.191.890.670.02
Book Value Per Share971.1112,743.04259,708.10138,971.8930,553.81-1,602.19
Tangible Book Value Per Share491.537,381.44259,708.05138,971.8630,553.80-1,602.19
Full-Time Employees34318---
Price to Book Ratio0.060.07-192.64-192.64--
Return on Assets-71.18-56.64-46.79-140.73-229.70-
Return on Equity-107.34-76.61-66.83-227.60-367.53-
Return on Invested Capital-86.65-93.79-110.51-138.07-174.14-
Quick Ratio1.723.363.792.142.060.42
Current Ratio1.743.363.792.552.950.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-13.49-7.75-6.25-4.30-1.80-0.78-0.13
Depreciation0.570.110.080.000.010.000.00
Other Funds (Non Cash)2.251.080.420.570.200.140.00
Funds from Operations-10.63-6.52-5.74-3.73-1.60-0.64-0.13
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital2.420.590.25-0.820.01-0.020.00
Cash from Operating Activities-8.21-5.93-5.49-4.56-1.59-0.66-0.13
Capital Expenditures-0.78-0.45-0.47-0.01-0.04-0.030.00
Net Assets From Acquisitions-8.01-2.160.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-0.13-0.03-0.140.000.000.000.00
Purchase of Investments-3.66-1.79-0.140.00---
Sale Or Maturity of Investments3.541.760.000.000.000.000.00
Other Uses0.00-0.130.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-8.92-2.77-0.61-0.01-0.03-0.030.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock29.5310.126.996.742.181.090.11
Repurchase of Common Pref Stock0.00-0.000.000.000.000.000.00
Sale of Common Pref Stock29.5310.126.996.742.181.090.11
Proceedsfrom Stock Options31.266.910.005.240.000.000.00
Issuance or Reduction of Debt, Net0.050.00-0.240.000.000.000.00
Change in Long Term Debt0.050.00-0.240.000.000.000.00
Issuance of Long Term Debt0.350.000.910.000.000.000.00
Reduction of Long Term Debt-0.300.00-1.150.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.180.000.02
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities29.5810.126.766.742.361.090.14
Exchange Rate Effect0.000.00-0.000.00-0.000.00-0.00
Net Change in Cash12.461.420.662.170.740.400.01
Free Cash Flow-8.99-6.38-5.50-4.57-1.62-0.69-0.13
Preferred Dividends (Cash Flow)--0.000.00---
Deferred Taxes & Investment Tax Credit-0.030.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments18.7915.095.978.506.315.92
Short Term Receivables0.600.540.340.370.200.05
Inventories0.930.250.100.130.000.00
Other Current Assets0.500.500.460.770.790.84
Total Current Assets20.8316.396.879.777.306.82
Net Property, Plant & Equipment6.703.992.131.660.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets9.035.663.873.512.072.07
Other Assets0.000.000.000.000.000.00
Total Assets36.5626.0312.8714.949.388.89
Short Term Debt Incl. Current Port. of LT Debt9.775.861.593.420.000.00
Accounts Payable1.270.660.700.550.270.38
Other Current Liabilities4.294.781.661.480.050.38
Total Current Liabilities15.3311.303.945.460.330.76
Long Term Debt4.472.101.060.990.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.030.030.03---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities19.8313.435.036.450.330.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity16.7412.617.848.499.058.13
Total Shareholders Equity16.7412.617.848.499.058.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity16.7412.617.848.499.058.13
Total Liabilities & Stockholders Equity36.5626.0312.8714.949.388.89
Book Value Per Share27.2065.09971.112,738.275,144.099,655.84
Tangible Book Value Per Share12.5235.87491.531,606.783,965.807,193.57
Full-Time Employees--34---
Price to Book Ratio0.060.920.370.460.350.40
Return on Assets-59.06-64.07----
Return on Equity-105.22-107.90----
Return on Invested Capital-13.87-33.78-33.53-27.38-6.21-19.30
Quick Ratio1.301.431.721.7722.388.97
Current Ratio1.361.451.741.7922.388.97

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.94-4.97-2.98-2.59-0.56-1.61
Depreciation0.310.170.060.040.000.02
Other Funds (Non Cash)-0.561.740.640.44-0.380.39
Funds from Operations-3.19-3.06-2.25-2.12-0.94-1.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.210.080.500.63-0.41-0.14
Cash from Operating Activities-1.99-2.98-1.75-1.49-1.35-1.35
Capital Expenditures0.03-0.36-0.35-0.10-0.010.00
Net Assets From Acquisitions-3.83-2.02-2.160.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.11-0.100.29-0.430.33-0.22
Purchase of Investments-1.44-1.44-0.22-0.57-0.57-0.43
Sale Or Maturity of Investments1.551.330.520.140.900.21
Other Uses0.000.001.67-1.67-0.130.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-3.68-2.48-0.55-2.200.20-0.22
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock9.7314.09-1E-065.711.472.94
Repurchase of Common Pref Stock0.000.000.000.000.00-0.00
Sale of Common Pref Stock9.7314.09-1E-065.711.472.94
Proceedsfrom Stock Options9.7314.09-1E-067.44-0.05-0.48
Issuance or Reduction of Debt, Net-0.270.320.000.000.000.00
Change in Long Term Debt-0.270.320.000.000.000.00
Issuance of Long Term Debt0.000.350.000.000.000.00
Reduction of Long Term Debt-0.27-0.030.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.4614.41-1E-065.711.472.94
Exchange Rate Effect0.000.000.000.000.00-0.00
Net Change in Cash3.798.95-2.302.020.321.38
Free Cash Flow-1.96-3.34-2.10-1.59-1.35-1.35

Revenue breakdown

United States2025: 590.08K
ITPackaging Solutions2025: 374.87K
Precision Engineering And Machining2025: 215.21K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.30%0.0M0.8M42.11K
2026-10-152.29%0.0M0.8M56.42K
2026-09-303.41%0.0M0.8M222.52K
2026-09-154.25%0.0M0.8M219.97K
2026-08-313.14%0.0M0.8M273.96K
2026-08-14-0.0M-287.60K
2026-07-319.70%0.0M0.5M294.67K
2026-07-1517.82%0.1M0.5M319.74K
2026-06-307.29%0.0M0.5M572.36K
2026-06-1513.24%0.1M0.5M806.31K
2026-05-2913.23%0.1M0.5M757.09K
2026-05-158.49%0.0M0.5M738.43K
2026-04-305.33%0.0M0.4M749.18K
2026-04-1521.48%0.0M0.2M724.52K
2026-03-31309.77%0.2M0.1M376.32K
2026-03-136.24%0.0M0.1M22.56K
2026-02-272.71%0.0M0.1M21.12K
2026-02-1311.07%0.0M0.0M17.61K
2026-01-302.84%0.0M0.0M5.44K
2026-01-153.62%0.0M0.0M4.84K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-01SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-22SCHEDULE 13D/ASEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-20SEC
2026-09-29SCHEDULE 13DSEC
2026-09-188-KCurrent report2026-09-18SEC
2026-09-028-KCurrent report2026-08-27SEC
2026-08-278-KCurrent report2026-08-21SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-098-KCurrent report2026-07-02SEC
2026-07-078-KCurrent report2026-06-30SEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-088-KCurrent report2026-06-05SEC
2026-06-058-KCurrent report2026-06-01SEC
2026-06-03SCHEDULE 13D/ASEC
2026-06-03SCHEDULE 13DSEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-27SCHEDULE 13G/ASEC
2026-05-15DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-11SEC
2026-05-04PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-05-04DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-05-04SEC
2026-04-288-KCurrent report2026-04-28SEC
2026-04-27DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342026-04-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
JANE STREET GROUP, LLC1.79%
MORGAN STANLEY1.17%
VANGUARD FIDUCIARY TRUST CO0.75%
GEODE CAPITAL MANAGEMENT, LLC0.53%
CITADEL ADVISORS LLC0.46%
UBS Group AG0.37%
VANGUARD CAPITAL MANAGEMENT LLC0.37%
Virtu Financial LLC0.37%
XTX Topco Ltd0.31%
Tower Research Capital LLC0.06%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.57%
Fidelity Series Total Market Index Fund0.11%
Fidelity Total Market Index Fund0.05%

OakChart. ELAB. Cached 15 minutes.

Some panels did not load: ratings, insider.